Cited by 174Cardiac electrophysiology and arrhythmiasCardiac Health and Mental HealthTreatment of Major Depression

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

A Comparison of the Risk of QT Prolongation Among SSRIs

Funk, Kylee A., Bostwick, Jolene R.·2013·Annals of Pharmacotherapy

DOI 10.1177/1060028013501994

Open this paper in CoChat — free account

Abstract

Objective : To report QT prolongation potential in selective serotonin reuptake inhibitors (SSRIs) in order to advise clinicians on safe use of SSRIs other than citalopram in light of citalopram warnings. Data Sources : Primary literature and case reports were identified through a systematic search. Data from drug manufacturers, package inserts, and the ArizonaCERT database were also utilized. Study Selection and Data Extraction : English-language studies and case reports were included. Data Synthesis : Studies demonstrate possible dose-related clinically significant QT prolongation with escitalopram. Fluoxetine, fluvoxamine, and sertraline at traditional doses demonstrate a lack of clinically significant increases in QTc in the majority of studies. Further, paroxetine monotherapy shows a lack of clinically significant QTc prolongation in all studies. However, case reports or reporting tools still link these SSRIs with QTc prolongation. Fluoxetine, escitalopram, and sertraline used in post–acute coronary syndrome patients did not demonstrate risk of QTc prolongation. Conclusion : For clinicians who choose not to use citalopram due to recent Food and Drug Administration (FDA) recommendations, other antidepressants within this class may be considered. When citalopram is not utilized based on risk factors for TdP, use of escitalopram is not likely the safest alternative. Based on current literature, fluoxetine, fluvoxamine, and sertraline appear to have similar, low risk for QT prolongation, and paroxetine appears to have the lowest risk. However, there are significant limitations in interpreting the studies, including varying definitions of significant QT prolongation. Therefore, choice of an alternative SSRI should be based on individual risk factors for arrhythmias and other patient-specific factors.

Integrity signals

Registry

Crossref · 10.1177/1060028013501994

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Pharmacotherapy: A Pathophysiologic Approach
(1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-5-447_3 · Cited by 2,402
Sertraline treatment of major depression in patients with acute MI or unstable angina
Glassman, A. H. (2002) · JAMA · doi:10.1001/jama.288.6.701 · Cited by 1,414
Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death
Glassman, A. H., & Bigger, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1774 · Cited by 821
What Clinicians Should Know About the QT Interval
Al‐Khatib, S. M., LaPointe, N. M. A., Kramer, J. M., & Califf, R. M. (2003) · JAMA · doi:10.1001/jama.289.16.2120 · Cited by 671
Relative Toxicity of Selective Serotonin Reuptake Inhibitors (SSRIs) in Overdose
Isbister, G. K., Bowe, S. J., Dawson, A. H., & Whyte, I. M. (2004) · Journal of Toxicology Clinical Toxicology · doi:10.1081/clt-120037428 · Cited by 432
QT interval and antidepressant use: a cross sectional study of electronic health records
Castro, V. M., Clements, C. C., Murphy, S. N., Gainer, V. S., D, M. F. M., Weilburg, J. B., Erb, J. L., Churchill, S. E., Kohane, I. S., Iosifescu, D. V., et al. (2013) · BMJ · doi:10.1136/bmj.f288 · Cited by 316
Citalopram, QTc Interval Prolongation, and Torsade de Pointes. How Should We Apply the Recent FDA Ruling?
Vieweg, W. V. R., Hasnain, M., Howland, R. H., Hettema, J. M., Kogut, C., Wood, M. A., & Pandurangi, A. K. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.12.002 · Cited by 268
Efficacy and Safety of Fluoxetine in the Treatment of Patients With Major Depression After First Myocardial Infarction: Findings From a Double-Blind, Placebo-Controlled Trial
Strik, J. J. M. H., Honig, A., Lousberg, R. L., Lousberg, A., Cheriex, E. C., Tuynman-Qua, H. G., Kuijpers, P. M. J. C., Wellens, H. J. J., & van Praag, H. M. (2000) · Psychosomatic Medicine · doi:10.1097/00006842-200011000-00007 · Cited by 255
Cardiovascular Effects of Fluoxetine in Depressed Patients With Heart Disease
Roose, S. P., Glassman, A. H., Attia, E., Woodring, S., Giardina, E. V., & Bigger, J. T. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.5.660 · Cited by 212
Drug‐induced long QT syndrome: hERG K+channel block and disruption of protein trafficking by fluoxetine and norfluoxetine
Rajamani, S., Eckhardt, L. L., Valdivia, C. R., Klemens, C. A., Gillman, B. M., Anderson, C. L., Holzem, K. M., Delisle, B. P., Anson, B. D., Makielski, J. C., et al. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706892 · Cited by 193
Drug‐induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)
Poluzzi, E., Raschi, E., Moretti, U., & Ponti, F. D. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1746 · Cited by 138
American Psychiatric Association Practice Guidelines for the Treatment of Patients With Major Depressive Disorder
American Psychiatric Association (2010) · doi:10.1176/appi.books.9780890423387.654001 · Cited by 134
Evaluation of the FDA Warning Against Prescribing Citalopram at Doses Exceeding 40 mg
Zivin, K., Pfeiffer, P. N., Bohnert, A. S. B., Ganoczy, D., Blow, F. C., Nallamothu, B. K., & Kales, H. C. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12030408 · Cited by 127 · cited 10×
“Furthermore, risk factors for TdP such as age, female gender, presence of hypokalemia, hypomagnesemia, bradycardia, and cardiovascular disease were often also not reported.55 In addition, many studies were small pharmacokinetic analyses, which may not be generalizable to a broad population; did not always use a broad…”
ResultInfluential
Antidepressant Use and Risk of Out-of-Hospital Cardiac Arrest: A Nationwide Case–Time–Control Study
Weeke, P. E., Jensen, A. K. G., Folke, F., Gislason, G., Olesen, J. B., Andersson, C., Fosbøl, E. L., Larsen, J. K., Lippert, F. K., Nielsen, S. L., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.368 · Cited by 111
Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia
Leonard, C. E., Bilker, W. B., Newcomb, C. W., Kimmel, S. E., & Hennessy, S. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2181 · Cited by 111
Torsades de PointesAssociated with High Dose Levomethadyl Acetate (ORLAAM®)
Deamer, R. L., Wilson, D. R., Clark, D., & Prichard, J. G. (2001) · Journal of Addictive Diseases · doi:10.1300/j069v20n04_02 · Cited by 105
Serum Levels and Cardiovascular Effects of Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors in Depressed Patients
de la Torre, B. R., Dreher, J., Malevany, I., Bagli, M., Kolbinger, M., Omran, H., Lüderitz, B., & Rao, M. L. (2001) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200108000-00019 · Cited by 104
A Comparison of Brain and Serum Pharmacokinetics of R-Fluoxetine and Racemic Fluoxetine: A 19-F MRS Study
Henry, M., Schmidt, M. E., Hennen, J. A., Villafuerte, R. A., Butman, M. L., Tran, P., Kerner, L. T., Cohen, B. M., & Renshaw, P. F. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300749 · Cited by 86
A Thorough QTc Study of 3 Doses of Iloperidone Including Metabolic Inhibition Via CYP2D6 and/or CYP3A4 and a Comparison to Quetiapine and Ziprasidone
Potkin, S. G., Preskorn, S., Hochfeld, M., & Meng, X. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31827c0314 · Cited by 78
Torsade De Pointes Resulting from the Addition of Droperidol to an Existing Cytochrome P450 Drug Interaction
Michalets, E. L., Smith, L., & Tassel, E. D. V. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17351 · Cited by 69
Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study
Martínez, C., Assimes, T. L., Mines, D. I., Dell’Aniello, S., & Suissa, S. (2010) · BMJ · doi:10.1136/bmj.c249 · Cited by 67
Comparative effects of fluoxetine and amitriptyline on cardiac function.
Upward, J., Edwards, J. G., Goldie, A., & Waller, D. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03397.x · Cited by 62
Electrocardiographic Effects of Fluoxetine and Doxepin in Patients With Major Depressive Disorder
Baker, B., Dorian, P., Sandor, P., Shapiro, C. M., Schell, C., Mitchell, J., & Irvine, M. J. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199702000-00004 · Cited by 51
Fluoxetine (Prozac) as a Cause of QT Prolongation
Varriale, P. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.4.612 · Cited by 49
The Safety and Tolerability of Duloxetine Compared With Paroxetine and Placebo
Nelson, J. C., Pritchett, Y., Martynov, O., Yu, J., Mallinckrodt, C. H., & Detke, M. J. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0404 · Cited by 44
A double-blind, placebo-controlled dose-finding study with sertraline.
Amin, M., Lehmann, H., & Mirmiran, J. (1989) · PubMed · Cited by 42
Cardiovascular Safety of One-Year Escitalopram Therapy in Clinically Nondepressed Patients With Acute Coronary Syndrome
Hanash, J. A., Hansen, B. H., Hansen, J. F., Nielsen, O. W., Rasmussen, A., & Birket‐Smith, M. (2012) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3182677041 · Cited by 42
Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Changes in the QTc interval after administration of flecainide acetate, with and without coadministered Paroxetine, in Relation to Cytochrome P450 2D6 Genotype: Data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects
Lim, K. S., Jang, I., Kim, B., Kim, J. W., Jeon, J., Tae, Y.-M., Yi, S., Eum, S., Cho, J., Shin, S., et al. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.04.002 · Cited by 39
QTc Prolongation Associated with Combination Therapy of Levofloxacin, Imipramine, and Fluoxetine
Nykamp, D. L., Blackmon, C. L., Schmidt, P. E., & Roberson, A. G. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e513 · Cited by 39
Cardiovascular effects of paroxetine
Kuhs, H., & Rudolf, G. A. E. (1990) · Psychopharmacology · doi:10.1007/bf02244107 · Cited by 38
QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: A case report and review of the literature
Lynch, D., Washam, J. B., & Newby, L. K. (2012) · Cardiology Journal · doi:10.5603/cj.2012.0078 · Cited by 38
QTc Prolongation and Torsades de Pointes in an Elderly Woman Taking Fluoxetine
Wilting, I., Smals, O. M., Holwerda, N. J., Meyboom, R. H. B., Bruin, M. L. D., & Egberts, T. C. G. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.325 · Cited by 37
Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients.
Laird, L. K., Lydiard, R. B., Morton, W. A., Steele, T. E., Kellner, C. H., Thompson, N. M., & Ballenger, J. C. (1993) · PubMed · Cited by 36
Paroxetine Does Not Affect the Cardiac Safety and Pharmacokinetics of Terfenadine in Healthy Adult Men
Martin, D. E., Zussman, B. D., Everitt, D. E., Benincosa, L. J., Etheredge, R. C., & Jorkasky, D. K. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199712000-00003 · Cited by 35
Effect of paroxetine on the electrocardiogram
Edwards, J. G., Goldie, A., & Papayanni-Papasthatis, S. (1989) · Psychopharmacology · doi:10.1007/bf00443420 · Cited by 33
Absence of Cardiovascular Adverse Effects of Sertraline in Children and Adolescents
Wilens, T. E., Biederman, J., March, J. S., Wolkow, R., FINE, C. S., Millstein, R., Faraone, S. V., GELLER, D. A., & Spencer, T. J. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199905000-00019 · Cited by 32
A Critical Evaluation of the Cardiac Toxicity of Citalopram: Part 1
Howland, R. H. (2011) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20111011-01 · Cited by 31
Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review
Tseng, P., Lee, Y., Lin, Y.-E., & Lin, P. (2011) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2011.10.005 · Cited by 28
Cardiovascular effects of fluvoxamine and maprotiline in depressed patients
Hewer, W., Rost, W., & Gattaz, W. F. (1995) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02191808 · Cited by 27
Coadministration of scrtraline with cisapride or pimozide: an open-label, nonrandomized examination of pharmacokinetics and corrected qt intervals in healthy adult volunteers
Alderman, J. A. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.07.013 · Cited by 27
Prolonged QT interval in an infant of a fluoxetine treated mother
Dubnov, G. (2005) · Archives of Disease in Childhood · doi:10.1136/adc.2004.064618 · Cited by 27
Abnormal QT prolongation and psychotropic drug therapy in psychiatric patients: Significance of bradycardia-dependent QT prolongation
Sadanaga, T., Sadanaga, F., Yao, H., & Fujishima, M. (2002) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2004.07.001 · Cited by 26
Influence of Coadministration of Fluoxetine on Cisapride Pharmacokinetics and QTc Intervals in Healthy Volunteers
Zhao, Q., Wojcik, M. A., Parier, J., & Pesco‐Koplowitz, L. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.2.149.34109 · Cited by 25
QT interval prolongation after sertraline overdose: a case report
de Boer, R. A., van Dijk, T. H., Holman, N. D., & van Melle, J. P. (2005) · BMC Emergency Medicine · doi:10.1186/1471-227x-5-5 · Cited by 24
Lithium therapy and prophylaxis.
Guy, S., & Silke, B. (1990) · PubMed · Cited by 23
Therapeutic advances: Paroxetine for the treatment of social anxiety disorder
Lydiard, R. B., & Bobes, J. (2000) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(2000)11:3 · Cited by 20
Electrocardiographic Findings during Extended Clinical Trials of Fluvoxamine in Depression: One Years Experience
Hochberg, H. M., Kanter, D. R., & Houser, V. P. (1995) · Pharmacopsychiatry · doi:10.1055/s-2007-979612 · Cited by 18
QT interval prolongation and torsade de pointes
Patanè, S., Marte, F., & Bella, G. D. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.05.100 · Cited by 17
Pharmacotherapeutic Determinants for QTc Interval Prolongation in Japanese Patients with Mood Disorder
Okayasu, H., Ozeki, Y., Fujii, K., Takano, Y., Saeki, Y., Hori, H., Horie, M., Higuchi, T., Kunugi, H., & Shimoda, K. (2012) · Pharmacopsychiatry · doi:10.1055/s-0032-1308969 · Cited by 14
Observation of QTc Prolongation in an Adolescent Girl During Fluvoxamine Pharmacotherapy
Brzozowska, A., & Werner, B. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0136 · Cited by 11
The impact of ziprasidone in combination with sertraline on visually-evoked event-related potentials in depressed patients with psychotic features
Moeller, O., Evers, S., Deckert, J., Baune, B. T., Dannlowski, U., Nguyen, D. H., Arolt, V., & Hetzel, G. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.06.021 · Cited by 8

Research works printed but not linked: 2

Guy S, Silke B. The electrocardiogram as a tool for therapeutic monitoring: a critical analysis. J Clin Psychiatry. 1990;51(suppl B):37-39.
10.1345/aph.16185. · DOI · Paper page

Sorted by citations

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G., M., Garas, W., Paleos, C., Gorman, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01336-3 · Cited by 1,004
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
Hicks, J. K., Bishop, J., Sangkuhl, K., Dj, M., Ji, Y., Leckband, S. G., Leeder, J. S., Graham, R., Chiulli, D., LLerena, A., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.147 · Cited by 1,001
The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 , CYP2C19 , CYP2B6 , SLC6A4 , and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants
Bousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., Singh, A. B., Ruaño, G., Mueller, D. J., Tsermpini, E. E., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2903 · Cited by 521

See all 174

Authors: Funk, K. A., & Bostwick, J. R.
Affiliations: University of Michigan (US)
ORCID: Funk, Kylee A.
Bostwick, Jolene R.
Venue: Annals of Pharmacotherapy
Publisher: SAGE Publications
Published: 2013-10
Volume: 47
Issue: 10
Pages: 1330-1341
ISSN: 0012-6578 (ISSN-L)
1060-0280
1542-6270
DOI: 10.1177/1060028013501994
OpenAlex: W2018099384
Cited by: 174
References: 52
Citations by year: 2026: 12 · 2025: 19 · 2024: 22 · 2023: 20 · 2022: 22 · 2021: 13 · 2020: 6 · 2019: 11 · 2018: 8 · 2017: 11 · 2016: 12 · 2015: 11 · 2014: 6
FWCI: 6.57
Type: journal article
Language: en
Open access: closed
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Annals of Pharmacotherapy (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: QT prolongation, selective serotonin reuptake inhibitors, citalopram, escitalopram, fluoxetine, fluvoxamine, sertraline, paroxetine, torsades de pointes, QTc interval, antidepressant safety, arrhythmia risk, acute coronary syndrome, FDA warning
MeSH terms: Antidepressive Agents, Humans, Long QT Syndrome, Risk, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Comparison of the Risk of QT Prolongation Among SSRIs

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks